References
- Broder L. E., Carter S. K. Pancreatic islet cell carcinoma I. Clinical features of 52 patients. Ann. Intern. Med. (1973); 79: 108–118
- Schein P. S., Rakieten N., Cooney D. A. Streptozotocin diabetes in monkeys and dogs, and it prevention by nicotinamide. Proc. Soc. Exp. Biol. Med. (1974); 143: 514–518
- Sadoff L. Nephrotoxicity of streptozotocin (NSC 85998). Cancer Chemother. Rep. (1970); 54: 457–459
- Myerowitz R. L., Sartiano G. P., Cavallo T. Nephrotoxic and cytoproliferative effects of streptozotocin. Cancer (1975); 38: 1550–1555
- Schein P., O'Connell M. J., Blom J. Clinical antitumor activity and toxicity of streptozotocin (NSC 85998). Cancer (1974); 34: 993–1000
- Prieur D. J., Young D. M., Davis R. D., et al. Procedures for preclinical toxicologic evaluation of cancer chemotherapeutic agents: Protocols of the laboratory of toxicology. Cancer Chemother. Rep. Part 3 (1973); 4: 1–30
- Battelle Columbus Laboratories Preclinical toxologic evaluation procedures manual. February, 1977
- Sadoff L. Patterns of intravenous glucose tolerance and insulin‐response before and after treatment with streptozotocin (NSC 85998) in patients with cancer. Cancer Chemother. Rep. (1972); 56: 61–69